
PKV'O ket qpwt kgpvu'O gcuwt go gpv'' S wcrkx{ 'Cunwt cpeg'Rt qi t co '' Y kpvgt '4235'' E qo r ct cdktkx{ 'Uvwf kgu''

Results for Round Robin LXXIII Fat-Soluble Vitamins and Carotenoids in Human Serum and Round Robin 38 Ascorbic Acid in Human Serum



Р **К**/**УКГ** '9:: 2/63

NIST Micronutrients Measurement Quality Assurance Program Winter 2013 Comparability Studies

Results for Round Robin LXXIII Fat-Soluble Vitamins and Carotenoids in Human Serum and Round Robin 38 Ascorbic Acid in Human Serum

> David L. Duewer Jeanice B. Thomas Chemical Sciences Division Materials Measurement Laboratory

This publication is available free of charge from: http://dx.doi.org/10.6028/NIST.IR.7880-41

November 2014



U.S. Department of Commerce Penny Pritzker, Secretary

National Institute of Standards and Technology Willie E. May, Acting Under Secretary of Commerce for Standards and Technology and Acting Director (This page intentionally blank)

Abstract

The National Institute of Standards and Technology coordinates the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. This report describes the design of and results for the Summer 2013 MMQAP measurement comparability improvement studies: 1) Round Robin LXXIII Fat-Soluble Vitamins and Carotenoids in Human Serum and 2) Round Robin 38 Total Ascorbic Acid in Human Serum. The materials for both studies were shipped to participants in January 2013; participants were requested to provide their measurement results by April 1, 2013.

Keywords

Human Serum Retinol, α-Tocopherol, γ-Tocopherol, Total and *Trans*-β-Carotene Total Ascorbic Acid

Table of Contents

Abstract	iii
Keywords	iii
Table of Contents	
Introduction	
Round Robin LXXIII: Fat-Soluble Vitamins and Carotenoids in Human Serum	
Round Robin 38: Vitamin C in Human Serum	2
References	
Appendix A. Shipping Package Inserts for RR73	A1
Appendix B. Final Report for RR73	B1
Appendix C. All-Lab Report for RR73	C1
Appendix D. Representative Individualized Report for RR73	D1
Appendix E. Shipping Package Inserts for RR38	E1
Appendix F. Final Report for RR38	F1
Appendix G. "All-Lab Report" for RR38	
Appendix H. Representative "Individualized Report" for RR38	

Introduction

Beginning in 1988, the National Institute of Standards and Technology (NIST) has coordinated the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. The MMQAP provides participants with measurement comparability assessment through use of interlaboratory studies, Standard Reference Materials (SRMs) and control materials, and methods development and validation. Serum-based samples with assigned values for the target analytes (retinol, alpha-tocopherol, gamma/beta-tocopherol, *trans*- and total beta-carotene, and total ascorbic acid) and performance-evaluation standards are distributed by NIST to laboratories for analysis.

Participants use the methodology of their choice to determine analyte content in the control and study materials. Participants provide their data to NIST, where it is compiled and evaluated for trueness relative to the NIST value, within-laboratory precision, and concordance within the participant community. NIST provides the participants with a technical summary report concerning their performance for each exercise and suggestions for methods development and refinement. Participants who have concerns regarding their laboratory's performance are encouraged to consult with the MMQAP coordinators.

All MMQAP interlaboratory studies consist of individual units of batch-prepared samples that are distributed to each participant. For historical reasons these studies are referred to as "Round Robins". The MMQAP program and the nature of its studies are described elsewhere. [1,2]

Round Robin LXXIII: Fat-Soluble Vitamins and Carotenoids in Human Serum

Participants in the MMQAP Fat-Soluble Vitamins and Carotenoids in Human Serum Round Robin LXXIII comparability study (hereafter referred to as RR73) received one lyophilized and four liquid-frozen human serum test samples for analysis. Unless multiple vials were previously requested, participants received one vial of each serum. These sera were shipped on dry ice to participants in January 2013. The communication materials included in the sample shipment are provided in Appendix A.

Participants are requested to report values for all fat-soluble vitamin-related analytes that are of interest to their organizations. Not all participants report values for the target analytes, and many participants report values for non-target analytes.

The final report delivered to every participant in RR73 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of the overall results that may be of broad interest. This cover letter is reproduced as Appendix B.
- The "All-Lab Report" that lists all of the reported measurement results, a number of consensus statistics for analytes reported by more than one participant, and the mean median and pooled SD from any prior distributions of the serum. This report also provides a numerical "score card" for each participant's measurement comparability for the more commonly reported analytes. This All-Lab Report is reproduced as Appendix C.

• An "Individualized Report" that graphically analyzes each participant's results for all analytes reported by at least five participants. This report also provides a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [3]. An example Individualized Report is reproduced as Appendix D.

Round Robin 38: Vitamin C in Human Serum

Participants in the MMQAP Vitamin C in Human Serum Round Robin 38 comparability study (hereafter referred to as RR38) received four frozen serum test samples and two frozen control sera. Unless multiple vials were previously requested, participants received one vial of each material. These sample materials were shipped on dry ice to participants in January 2013. The communication materials included in the sample shipment are provided in Appendix E.

The test and control serum materials were prepared by adding equal volumes of 10 % metaphosphoric acid (MPA) to human serum that had been spiked with ascorbic acid. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, the participants report only total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid).

The final report delivered to every participant in RR38 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of overall results that may be of broad interest. This cover letter is reproduced as Appendix F.
- The "All-Lab Report" that summarizes all of the reported measurement results and provides several consensus statistics. This All-Lab Report is reproduced as Appendix G.
- An "Individualized Report" that graphically analyzes each participant's results for TAA, including a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [3]. An example Individualized Report is reproduced as Appendix H.

References

- Duewer DL, Brown Thomas J, Kline MC, MacCrehan WA, Schaffer R, Sharpless KE, May WE, Crowell JA. NIST/NCI Micronutrients Measurement Quality Assurance Program: Measurement Repeatabilities and Reproducibilities for Fat-Soluble Vitamin-Related Compounds in Human Sera. Anal Chem 1997;69(7):1406-1413.
- 2 Margolis SA, Duewer DL. Measurement Of Ascorbic Acid in Human Plasma and Serum: Stability, Intralaboratory Repeatability, and Interlaboratory Reproducibility. Clin Chem 1996;42(8):1257-1262.
- 3 Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT, Sowell AL. Micronutrients Measurement Quality Assurance Program: Helping Participants Use Interlaboratory Comparison Exercise Results to Improve Their Long-Term Measurement Performance. Anal Chem 1999;71(9):1870-1878.

Appendix A. Shipping Package Inserts for RR73

The following three items were included in each package shipped to an RR73 participant:

- Cover letter
- Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter and datasheet were enclosed in a sealed waterproof bag along with the samples themselves. The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.



January 21, 2013

Dear Colleague:

Enclosed are samples for the first fat-soluble vitamins and carotenoids in serum study (Round Robin LXXIII) for the 2013 NIST Micronutrients Measurement Quality Assurance Program. The set of samples (Sera 392- 396) consists of one vial of lyophilized serum and one vial each of four liquid-frozen serum samples for analysis along with a form for reporting your results. These samples should be stored in the dark at or below -20 °C upon receipt. When reporting your results, please submit one value for each analyte for a given serum sample. If a value obtained is below your limit of quantification, please indicate this result on the form by using NQ (*Not Quantified*). Results are due to NIST by April 1, 2013. Results received more than two weeks after the due date may not be included in the summary report for this round robin study. The feedback report concerning the study will be distributed in May 2013.

Samples should be allowed to stand at room temperature under subdued light until thawed. We recommend that sample mixing be facilitated with 3 to 5 min agitation in an ultrasonic bath or at least 15 min at room temperature with intermittent swirling. (CAUTION: Vigorous shaking will cause foaming and possibly interfere with accurate measurement. The rubber stopper contains phthalate esters that may leach into the sample upon intermittent contact of the liquid sample with the stopper. These esters absorb strongly in the UV region and elute near retinol in most LC systems creating analytical problems.) Water should not be added to the liquid-frozen samples.

For consistency, we request that laboratories use the following absorptivities (dL/g \cdot cm): retinol, 1843 at 325 nm (ethanol); retinyl palmitate, 975 at 325 nm (ethanol); α -tocopherol, 75.8 at 292 nm (ethanol); γ -tocopherol, 91.4 at 298 nm (ethanol); α -carotene, 2800 at 444 nm (hexane); β -carotene, 2560 at 450 nm (ethanol), 2592 at 452 nm (hexane); and lycopene, 3450 at 472 nm (hexane).

Please report your results for Round Robin LXXIII by e-mail to david.duewer@nist.gov or fax to 301-977-0685. If you have questions or comments regarding this study, please call me at (301) 975-3120 or email me at jbthomas@nist.gov

Sincerely.

Jeanice Brown Thomas Program Coordinator/Research Chemist: Analytical Chemistry Division Material Measurement Laboratory



Date: _____

Round Robin LXXIII: Human Sera

NIST Micronutrients Measurement Quality Assurance Program

Analyte	392	393	394	395	396	Units*
total retinol						
trans-retinol						
retinyl palmitate						
α -tocopherol						
γ/β-tocopherol						
δ-tocopherol						
total β-carotene						
trans-β-carotene						
total cis-β-carotene						
total α -carotene						
total lycopene						
trans-lycopene						
total β-cryptoxanthin						
total α -cryptoxanthin						
total lutein						
total zeaxanthin						
total lutein&zeaxanthin						
total coenzyme Q10						
ubiquinol (QH ₂)						
ubiquinone (Qox)						
phylloquinone (K1)						
25-hydroxyvitamin D						
Phytoene						
Phytofluene						
-						

* we prefer μg/mL

Were the samples frozen when received? Yes | No

Comments:

Fat-Soluble Vitamins Round Robin LXXIII NIST Micronutrients Measurement Quality Assurance Program

Packing List and Shipment Receipt Confirmation Form

This box contains: one vial each of the following five FSV M²QAP sera

Serum	Form	Reconstitute?	Vial/Cap
#392	Lyophilized	Yes	5 mL clear / silver
#393	Liquid frozen	No	5 mL clear / silver
#394	Liquid frozen	No	2 mL amber / blue
#395	Liquid frozen	No	2 mL clear / green
#396	Liquid frozen	No	2 mL clear / black

Please 1) Open the pack immediately

- 2) Check that it contains all of the above samples
- 3) Check if the vials are intact
- 4) Store the sera at -20 °C or below until analysis
- 5) Email (david.duewer@nist.gov) or fax (301-977-0685) us the following information:

1) Date this shipment arrived: _____

- 2) Are all five sera vials intact? Yes | No If "No", which one(s) were damaged?
- 3) Was there any dry-ice left in cooler? Yes | No
- 4) Did the samples arrive frozen? Yes | No
- 5) At what temperature are you storing the serum samples? _____ °C
- 6) When do you anticipate analyzing these samples? _____

Your prompt return of this information is appreciated.

The M²QAP Gang

Appendix B. Final Report for RR73

The following three pages are the final report for RR73 as provided to all participants:

- Cover letter.
- An information sheet that:
 - o describes the contents of the "All-Lab" report,
 - o describes the content of the "Individualized" report,
 - describes the nature of the test samples and details their previous distributions, if any, and
 - summarizes aspects of the study that we believe may be of interest to the participants.



May 16, 2013

UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-

Dear Colleague:

Enclosed is the summary report of the results for "Round Robin" LXXIII (RR73) of the 2013 NIST Micronutrients Measurement Quality Assurance Program (M²QAP) for the fat-soluble vitamins and carotenoids in human serum. Included in this report are: 1) a summary of data and measurement comparability scores for all laboratories, 2) a detailed graphical analysis of your results; and 3) a graphical summary of your measurement comparability. RR73 (Sera 392 - 396) consisted of one vial of lyophilized serum and one vial each of four liquid-frozen serum samples. Details regarding the samples can be found in the enclosed report.

Your overall measurement comparability is summarized in the "Score Card" summary, page 7 of the All Lab Report. Combined results rated 1 to 3 are within 1 to 3 standard deviations of the assigned value, respectively; those rated 4 are >3 standard deviations from the assigned value. Similar information is presented graphically in the "target plots" that are the last page of your Individualized Report. If you have concerns regarding your laboratory's performance, please contact us for consultation.

Samples for the second set of fat-soluble vitamins and carotenoids in serum interlaboratory exercise (RR74) will be shipped starting June 10, 2013. Please contact us immediately if this schedule is problematic for your laboratory.

We are currently in the process of providing on-line documentation of data and reports from the MMQAP studies (past and present). The results for Round Robin 71 Fat-Soluble Vitamins and Carotenoids in Human Serum and and Round Robin 36 Ascorbic Acid in Human Serum are available at: http://www.nist.gov/manuscript-publication-search.cfm?pub_id=911458. Click on the DOI link to access the manuscript. Data summaries have been altered to ensure confidentiality of identification codes assigned to laboratories. We will update you as additional on-line documents become available.

If you have questions or concerns regarding this report, please contact David Duewer at 301-975-3935; e-mail: david.duewer@nist.gov or me at 301-975-3120; e-mail: jbthomas@nist.gov; or fax: 301-977-0685.

Sincerely,

Jeanice Brown Thomas, M.B.A. Research Chemist Analytical Chemistry Division Material Measurement Laboratory

Enclosures

Cc: L.C. Sander

David L. Duewer, Ph.D. Research Chemometrician Analytical Chemistry Division Material Measurement Laboratory



The NIST MMQAP Round Robin LXXIII (RR73) report consists of:
--

Page	All-Lab Report
1-5	A listing of all results and statistics for analytes reported by more than one participant.
6	A listing of the analytes reported by only one participant and a legend for the list of results and statistics.
7	The text Comparability Summary ("Score Card") of measurement performance.
р	
Page	Individualized Report
Page 1	Individualized Report Your values, the number of labs reporting values, and our assigned values.
Page 1 2 to	<u>^</u>
1	Your values, the number of labs reporting values, and our assigned values.

Samples. Five samples were distributed to each participant in RR73. Unfortunately, the sample distributed as Serum 394 was a mixture of two materials. Fortunately, the two materials have distinctive levels for several analytes and we have been able to unambiguously identify who got which material. We have *post-facto* designated these two materials Serum 394a and Serum 394b. The All Lab Report therefore lists values for six samples. The Individualized Reports for every participant reflect the results just for the five materials that they evaluated.

Serum	Description	Prior Distributions
392	Lyophilized, multi-donor stripped serum augmented with retinol, retinyl palmitate, α - and γ -tocopherol, α - and β -carotene, lycopene, β -cryptoxanthin, lutein, and zeaxanthin prepared in 1995.	#224:RR38-9/96
393	Liquid-frozen, multi-donor heparin-treated plasma material augmented with glycyrrhetinic acid prepared in 1989.	First MMQAP distribution
394a	Fresh-frozen, native, single donor serum prepared in 1999.	#271:RR49-3/01, #275:RR50-9/01, #279:RR51-3/02, #296:RR54-9/03, #308:RR56-9/04
394b	Liquid-frozen, multi-donor serum augmented with <i>trans</i> -β-carotene in a lipoprotein carrier prepared in 2008.	#353:RR65-3/09, #371:RR68-9/10
395	Fresh-frozen, native, multi-donor serum prepared in 2011. This material has relatively high contents of α - and β -carotene.	#382:RR71-3/12
396	Fresh-frozen, native, multi-donor serum prepared in 2011.	#385:RR71-3/12

Results

- Serum 392. This serum was constructed to test whether it was practical to spike sera with very lipophilic analytes. While we did not fully achieve the targeted levels for the carotenoids, the augmentation method used appeared to be relatively effective. This distribution of the material was intended to access the material's stability over time and storage. The median value for many, but not all, of the analytes is lower than that of 18 years ago. We speculate that due to the aging of the material, the augmented analytes in this lyophilized material have become more difficult to reconstitute and/or extract.
- 2) Serum 393. This material was prepared as part of an investigation into the chemopreventative potential of glycyrrhetinic acid (the main metabolite of the glucoside glycyrrhizin obtained from licorice root, *Glycyrriza glabra*). This relatively polar compound's absorbance maxima is at 248 nm and should not interfere with the analysis of the usual MMQAP analytes. However, if any of your results are uniquely high in Serum 393, please check the chromatogram for evidence of interference. If you find such evidence, please contact JBThomas@nist.gov.
- 3) <u>Sera 394a and 394b</u>. We apologize for the confusion. We unintentionally combined amber vials with blue caps that were labeled "271" and "371". The median levels and variability of the results for both "Serum 394" materials are essentially unchanged from their prior levels.
- 4) <u>Sera 395 and 396</u>. The median levels and variability of the results for both of these relatively new materials are essentially unchanged from their prior levels.

Appendix C. "All-Lab Report" for RR73

The following seven pages are the "All-Lab Report" for RR73 as provided to all participants, with two exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.

The data summary in the "All-Lab Report" has been altered to ensure confidentiality of identification codes assigned to laboratories.

	330	1.75		1.60		1.84	1.70	1.81						1.80				00	1.00	1.70	1 85	1.98)	1.86	1.23	1.89	1.70			1	۲. <i>۲</i>	1	1.76	18	1.23	1.80	1.98	0.08	2		1.77 0.09	
g/mL		1.42		1.30		1.41	1.37	1.36						3.00 1.50					4.1	1.43		1.46	2	1.39	0.92	1.51	1.12				1.40		1.35					0.0	4		1.36 0.09	1.39
erol, L	0.948 0.94D			2.90										3.00						2 7 G	1	3.31	5	3.13			2.70							9			3.31	0.28	0		3.15 0.33	2.95
<u>γ/β-Tocopherol, µg/mL</u>		2.00 1.84				1.89	1.80	1.95										5	1.91	1.09	1 00				1.34	2.01					1.77		1.87			1.89		0	9	24	1.96 0.15	1.89
-		0.82		0.70				0.78						0.00						0.20				0.83	0.60	0.84	0.73				c/.0 .		0			0.81		0	12	0		0.81
	_	4.33 3.85		3.70				4.33						3.70					0/.0					3.62			3.76				3.84		4					Ö			3.87 0.46	3.96
		8 7.14 8 7.14	6 10														3 7.40			1.03						3 7.40			8.00				\sim			3 7.30		0.5			3 7.51 3 0.76	3 7.30
g/mL	2622	11.73	9.30	~		11.79	11.51	12.27	10.37	10.80	11.20	9.83		•	12.39	12.00	11.33			0 75	· ·				10.14	11.93	11.95		10.30				11.21					0.8			11.33 1.23	11.23
erol, μ(0948 0940				5.2									8.4						7 1		10.2	6.1	7.4			8.4					8.8 8					-	-	18		7.9 0.6	8.4 1.4
a-Tocopherol, µg/mL	004a	0.90 6.83	6.30										7.00				7.40			40.7	6,60				6.43	6.96			6.30		1.64		7.15	22				0.34	Ω		7.11 0.57	6.92
α-T ₀		6 4.09 9 4.12	4 10														4.20								2 4.09		3 4.91		4.30				က်					0.2	9	0	~ 10	4.15
	282	0.03 8.49	7 40	9.00	7.30	8.56	8.88	8.39	7.91	8.60	8.20	7.44	8.19	8.70	8.51	00.6	8.10	0	0.47	00.01	707	10.46	6.38	7.13	8.12	8.41	8.88		8.10	0	8.89	9.60	8.62	31	6.38	8.47	10.46	0.61		45	8.28 0.55	8.47
000	390	0.006				0.013															0.047	1000	h		0.014					000	<0.02		0.019	9	0.006	0.017	0.047	0.010	63	5	0.014 0.012	0.017
/mL		00.0				0.054															0 070				0.047						0.031	!	0.047	ω	0.031	0.055	0.087	0.016	30		0.070 0.009	0.055
ate, µg	394D					U																na (U									0	U	Ŭ	Ŭ	Ŭ			0.014 (0.011 (0.011 (0.011)	
-=		0.048 0.044				0.024															0.084	5			0.043					100	0.025		0.037	7	0.024	0.043	0.084	0.009	21		0.055 0 0.014 0	0.043
tetinyl		0.004 0.				nd 0.															0 014 0		5		0.007 0.														20	0	o o	0.007 0
		0.070 0.0				0.049 n															0.085.01				0.083 0.0					0	0.059 <0.02								26	15	43 29	
			<i>т</i>	10			Ş	4	Ŋ	0	0	4	4	0	Ņ	0	5	c	N C	כ ש				2			0	0	-												3 0.243 4 0.129	· · · · · ·
		0.486	3 0.513 1 0.412														· ≥0.45			020.0									7 0.551				0.4					0.04	7		0.024	3 0.475
Ε		0.500	0.463 0.401			0.474	0.486	0.480	0.426	0.460	0.420	0.451			0.456	0.430	≥0.44	07.0	0.404						0.438				0.507	0			0.5					0.03			0.460	0.463
ol, µg/	334D			0.300	0.240									0.320						0 257		0.348	0.313	0.324			0.391	0.280				0.321		10	0.240	0.317	0.391	<u>.</u>	1	31	0.313 0.024	0.317
Total Retinol, µg/	0243	0.470 0.484	0.489 0.436			0.470	0.481	0.465	0.426	0.460	0.400	0.484	0.516		0.505	0.470	≥0.46		0.409	0.490	0 490	001.0			0.459				0.512		0.459		0.445	21	0.400	0.470	0.516	0.021	4	37	0.467 0.313 0.040 0.024	0.470
Tota		0.272 0.272	0.289 0.226		0.240	0.265	0.229	0.260	0.226	0.200	0.240			0.240	0.194		≥0.229		10.0	0.280		0.245	0.224	0.273	0.231		0.229		0.259					30	0.120 0.400 0.240	0.240 0.470 0.317	0.365		1	0		0.240 0.470 0.317
000		0.714 0.714	0.717 0.623														≥ 0.65 ≥		0.104						0.641				0.748										ω	47	0.690 0.057	0.660
L		FSV-BB 0	FSV-BC C															FSV-BS							FSV-CI 0	FSV-CO					PSV-EZ			z	Min C	Median C	Max C		eCV		Median _{past} C SD _{past} C	NAV 0

All Lab Report

Page 1 / 7

	392 393	393 394a 394b	33 394a 394b 395	9E 396	392	393	394a 394b 39	395	396	392 393	394a	394b 39	395 396	392	393	393 394a 394b 395	394b 395	5 396
	0.749 0.040 0.686 0.046	0 0.117 6 0.129	0.0	0.083 0.126 0.093 0.093	0.299 0.323	0.019 0.014	0.332 0.319	0.636 0.705	0.052 0.048	0.286 0.014 0.311 0.011	0.309 0.301		0.597 0.045 0.668 0.047	0.013 0.011		0.023 0.018	0.039 0.037	39 0.007 37 0.001
FSV-BU FSV-BE FSV-BF FSV-BG FSV-BH FSV-BJ FSV-BK					0.290 < 0.108 0.350 0.381 0.381 0.192	<0.02 nq 0.016 nq nq	0.300 0.372 0.338 0.280	0.670 0.393 0.696 0.739 0.739	0.050 0.056 0.057 0.046 0.034									
FSV-BL FSV-BL FSV-BN FSV-BN FSV-BNa FSV-BD FSV-BP FSV-BP					0.293 0.282 0.363 0.222	0.012 0.031 0.053 0.053	0.318 0.307 0.203 0.311	0.609 0.564 0.616 0.651	0.045 0.047 0.053 0.329	0.230 0.017 0.250	7 0.250	0.7	0.468 0.033	0.052	0.014 0.057	0.057	0.096	96 0.014
	0.485 0.079 0.111			0.070	≥0.443 0.360 0.335 0.240 0.221 0.427	<i>nq</i> 0.015 0.018 0.018 0.006 0.066	≥0.448 0.328 0.316 0.388 0.387 0.387	≥0.762 0.683 0.664 0.545 0.545 0.643 0.643	≥0.13 0.053 0.065 0.048 0.065 0.065	0.443 <i>nq</i> 0.317 0.013	0.448 3 0.281	0.0	0.762 0.130 0.582 0.048	0.012	bu	0.017	0.037	37 0.001
	ng ng 0.629 0.128		0.167 0.6 0.167 0.1	0.659 <i>nq</i> 0.139 0.141	0.328 0.259 0.347 0.632	0.015 0.009 0.021 0.088	0.294 0.343 0.354 0.279	0.667 0.720 0.705 0.674	0.054 0.041 0.061 0.120	0.317 0.013		.278 0.6	0.278 0.626 0.050	0.011	0.005	0.0	0.016 0.040	40 0.005
FSV-EE FSV-EZ FSV-FK							0.321	0.593 <0.059	<0.059									
FSV-FZ N 4 Min 0.485 Median 0.658 Max 0.749 eSD 0.089 eSD 0.089	0.06 0.06 0.12 0.02 0.02	3 0.111 0.117 0.129	2 0.167 0.167 0.167	5 4 0.083 0.070 0.093 0.109 0.659 0.141 0.015 0.035 16 32	0.59/ 22 0.108 0.325 0.632 0.073	0.020 17 0.006 0.018 0.088 0.006 35	0.375 15 7 0.203 0.249 0.328 0.294 0.388 0.294 0.388 0.294 0.25 0.025 0.025 0.025	0.725 22 0.393 0.666 0.801 0.066	0.070 21 21 0.034 0.053 0.329 0.011	6 5 0.230 0.011 0.314 0.013 0.443 0.017 0.023 0.002 7 13	5 0.250 0.301 0.448 0.030	1 0.278 0.6 0.7 0.0	6 6 0.468 0.033 0.612 0.047 0.762 0.130 0.064 0.004 10 8	5 0.011 0.052 0.001 0.001	4 0.003 0.005 0.014 0.002	4 0.017 0.020 0.(0.057 0.004	1 5 0.037 0.016 0.039 0.096 0.096	5 5 5 37 0.001 39 0.005 96 0.014 02 0.005
		6 0.132 0.053	4 0.087 0.016	0.0	32 32 0.624 0.103		29 21 29 21 0.350 0.305 0.040 0.053	0.0	18 0.055 0.007	0.587 0.103	13 0.323 0.027	7 0.288 0.6 0.027 0.1	0.0 0.0	0.027 0.027 0.019	5 0		6 4 0.016 0.038 0.003 0.005	
NAV 0.0 NAU	0.658 0.062	2 0.117	0.0	0.093 0.109 0.023	0.325 0.073	0.018 0.008	0.328 0.294 0.047 0.043	0.066 0.090	0.053 0.011	0.314 0.013 0.034 0.007	3 0.301 7 0.032	0.0	0.612 0.047 0.064 0.009	0.012 0.004	0.005	0.020	0.039 0.015	39 0.005 15 0.005

Lab	392	393	393 394a 394b 395	394b	395	396	392	393	393 394a 394b 39	394b	395 396	392	393 394a 394b 39	394b	395 396	6 392		3 394a	393 394a 394b 395	395	396
FSV-BA (FSV-BB (FSV-BC FSV-BC FSV-BD	0.372 (0.347 (0.004 0.003	0.030 0.025		0.340 0.020 0.343 0.018	0.020 0.018	0.296	0.135 0.125	0.307 0.289		0.260 0.214 0.284 0.208	0.204 0.071 0.173 0.059	71 0.171 59 0.137		0.130 0.104 0.110 0.085		0.059 0.011 0.051 0.010	11 0.061 10 0.050		0.066	0.101 0.091
	0.344 (0.466 0.413	0.008 nq nq	0.033 0.022 nq		0.326 (0.367 (0.383	0.024 0.018 nq	0.338 0.469 0.305	0.147 0.165 0.201	0.340 0.387 0.328	000	0.280 0.248 0.352 0.272 0.276 0.258	0.230 0.078 0.191	78 0.191	-	0.138 0.123	23 0.055 0.082 <i>nq</i>	55 0.011 82 nq 7 nq	11 0.054 0.067 <i>nq</i>		0.067 0.088 0.066 0.066	0.103 0.126 0.080
FSV-BM FSV-BN (FSV-BNa (FSV-BNa (0.393 (0.374	0.003 <i>bn</i>	0.040 0.041	00	0.355 0.020 0.333 0.023	0.020 0.023	0.324 0.327	0.141 0.164	0.367 0.369	00	0.307 0.251 0.349 0.284	 0.153 0.068 0.180	38 0.180	-	0.127 0.120	20 0.049	49 0.010 44 0.017	10 0.049 17 0.048		0.051	0.094 0.082
	0.051	pu	0.010	-	0.350 (0.024	0.742	0.220	0.143	0	0.271 0.232					0.094	94 0.090	90 0.046		0.062	0.143
	0.620 (0.417 (0.434 (0.355 (0.355 (0.684 (0.597	0.073 0.007 0.005 0.006 0.006 0.015 <i>nq</i>	0.068 0.031 0.026 0.026 0.017	0.026 0.050 0	0.432 (0.347 (0.376 (0.376 (0.376 (0.376 (0.540 (0.525 (0.041 0.026 0.029 0.023 0.023 0.015 0.033	0.565 0.315 0.335 0.235 0.275 0.385	0.267 0.123 0.133 0.133 0.099 0.136 0.152	0.815 0.297 0.305 0.332 0.332 0.332	0 0.362 0 0.543 0 0.543	0.399 0.452 0.292 0.219 0.274 0.231 0.224 0.206 0.226 0.234 0.309 0.280	0.315 0.136 0.168 0.056	36 0.348 56 0.139		0.159 0.188 0.121 0.099	88 0.123 99 0.057 0.052 0.052 0.029	23 0.069 57 0.012 52 0.012 29 0.006 81 0.019	 39 0.185 12 0.056 12 0.056 16 19 	0.058 0.128	0.124 0.058 0.071 0.042 0.042 0.105	0.190 0.095 0.092 0.071 0.124
	0.471 (0.333 (0.333 (0.005 0.008	0.028	0.042 0	0.459 0.030 0.338 0.020	0.030	0.367 0.376	0.154 0.140	0.336	0.513 0	0.340 0.273 0.276 0.239	0.264 0.083	8	0.274	0.274 0.157 0.131		0.069 0.020	0	0.129 0.104 0.129	0.104	0.129
N 16 Min 0.051 Median 0.403 Max 0.684 eSD 0.086 eCV 21	N 16 Min 0.051 (dian 0.403 (Max 0.684 (eSD 0.086 (eSCV 21	11 0.003 0.006 0.073 0.002 41	12 0.010 0.029 0.068 0.008 29	3 0.026 0.042 0.050 0	16 0.326 0.353 0.540 0.540 0.025 7	15 0.015 0.023 0.041 0.005 21	16 0.242 0.331 0.742 0.052 16	16 0.099 0.144 0.267 0.022 15	13 0.143 0.332 0.815 0.052 0.052	3 0.362 0 0.513 0 0.543 0 0	16 16 16 0.224 0.206 0.282 0.243 0.399 0.452 0.039 0.035 0.039 12 16	7 0.153 0.0 0.204 0.0 0.315 0.1 0.053 0.0 26	7 6 56 0.137 71 0.176 36 0.348 17 0.038 24 22	1 0.274	7 7 0.110 0.085 0.130 0.120 0.159 0.188 0.014 0.024 10 20	1	0.0.0	12 10 006 0.046 112 0.054 190 0.185 005 0.008 43 14	3 0.058 0.128 0.129	14 0.042 0.066 0.124 0.013 20	14 0.071 0.098 0.190 0.025 0.025 25
Nedianpast SDpast NAV	28 0 0.428 0.082 0.403 0.006		24 0.030 0.007 0.029	17 0.033 (0.007 (0.042 (15 15 0.384 0.025 0.117 0.004 0.353 0.023	15 0.025 0.004 0.023	28 0.377 0.086 0.331	0 0.144	24 0.353 C 0.054 C 0.332 C	16 0.506 0 0.078 0 0.513 0	13 13 13 0.278 0.237 0.056 0.053 0.056 0.243	8 8 0 7 0.288 5 0.063 0.003	0 11 0.186 0.041 71 0.176	8 0.234 0.028	6 6 0.132 0.119 0.021 0.022 0.130 0.120	0.0	20 0 60 15 57 0.012	0 24 0.054 0.009	17 0.089 0.013 0.128	14 0.065 0.005 0.066	14 0.106 0.034 0.098
NAU (NAU 0.100 0.003		0.010		0.088 (0.008	0.074		0.074		0.065 0.058	0.053			0.023 0.024					0.016	0.025

All Lab Report

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Lab	392	393	394a	394b		396	392	393	3 394a 394b 3	4b 395	5 396	392	393	394a	393 394a 394b 395	395	396	392	393	393 394a 394b 395	394b	395	396
0.000 0.000 0.000 0.000 0.000 0.000 0.119 0.019 <td< td=""><td>SV-BA SV-BB SV-BC SV-BC</td><td></td><td>0.006 0.007</td><td>0.031 0.023</td><td></td><td>0.026 0. 0.020 0.</td><td></td><td>0.128 (</td><td></td><td>0.097</td><td>0.15</td><td></td><td></td><td>3 0.014</td><td></td><td></td><td>0.043</td><td>0.042</td><td></td><td></td><td>0.103 0.140</td><td></td><td></td><td>0.105 0.139</td></td<>	SV-BA SV-BB SV-BC SV-BC		0.006 0.007	0.031 0.023		0.026 0. 0.020 0.		0.128 (0.097	0.15			3 0.014			0.043	0.042			0.103 0.140			0.105 0.139
0.040 0.006 0.024 0.026 0.026 0.026 0.015 0.016 0.015 0.016 0.015 0.016 0.015 0.016 0.015 0.016 0.015 0.016 0.015 0.016 0.015 0.015 0.016 0.016 0.016 0.015 <td< td=""><td>SV-BE SV-BF SV-BG SV-BH SV-BH SV-BL SV-BL</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.077 0.081</td><td>0.12</td><td>33 0.06 55 0.08</td><td></td><td>0.009</td><td>0.033</td><td></td><td>0.027</td><td>0.035</td><td>0.193 0.209</td><td>0.040</td><td>0.118 0.110</td><td>00</td><td></td><td>0.116 0.104</td></td<>	SV-BE SV-BF SV-BG SV-BH SV-BH SV-BL SV-BL									0.077 0.081	0.12	33 0.06 55 0.08		0.009	0.033		0.027	0.035	0.193 0.209	0.040	0.118 0.110	00		0.116 0.104
0040 0.024 0.025 0.015 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.155 0.066 0.161 0.155 0.066 0.161	V-BM SV-BN /-BNa						0	0.143 ().040		0.13	3 0.08		0.020			0.028	0.032	0.196 0.208	0.032 0.061		00		0.105 0.119
0.040 0.0264 0.026 0.026 0.026 0.038 0.149 0.338 0.149 0.373 0.166 0.165 0.040 0.118 0.0167 0.165 0.0167 0.165 0.0167 0.165 0.165 0.165 0.165 0.165 0.165 0.165 0.167 0.167 0.167 0.165 0.167 0.167 0.167 0.167 0.165 0.165 0.165 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.126																			0.160	0.152	0.096	0		0.113
0.064 0.011 0.058 0.038 0.036 0.284 0.066 0.288 0.237 0.051 0.281 <th< td=""><td>SV-BS SV-BT SV-BT SV-BU SV-BU</td><td></td><td>0.006</td><td>0.024</td><td>-</td><td>0.022 0.</td><td></td><td>0.212 (</td><td>0.054 (</td><td>0.258</td><td>0.25</td><td>52 0.17</td><td></td><td>0.095</td><td>0.121</td><td></td><td>0.094</td><td>0.102</td><td>0.338 0.201 0.216 0.197</td><td>0.149 0.042 0.026 0.026</td><td></td><td></td><td></td><td>0.272 0.119 0.124 0.134</td></th<>	SV-BS SV-BT SV-BT SV-BU SV-BU		0.006	0.024	-	0.022 0.		0.212 (0.054 (0.258	0.25	52 0.17		0.095	0.121		0.094	0.102	0.338 0.201 0.216 0.197	0.149 0.042 0.026 0.026				0.272 0.119 0.124 0.134
1 0.135 0.019 0.070 0.129 0.007 0.011 0.021 0.272 0.031 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.251 0.144 0.1			0.011		0.058	0.039 0.	027												0.284	0.086	Ö			0.201
4 3 1 4 6 5 6 5 5 4 0.015 0.025 0.011 0.112 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.011 0.015 0.014 0.015 0.014 0.015 0.014 0.015 0.014 0.015 0.014 0.015	V-CG V-CG V-CC V-CO V-CD						<u> </u>	0.135 (0.019 (0.070	0.12	0.0 <u>6</u>		0.011	0.021		0.015	0.024						0.158 <i>0.092</i>
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	V-EE SV-EZ SV-FZ SV-FZ																							
4 0 6 5 4 14 0 16 8 4 11 0 14 7 0 0 20 0 23 17 14 0.042 0.025 0.031 0.023 0.021 0.148 0.089 0.124 0.137 0.061 0.222 0.119 0.182 0.160 0.042 0.005 0.008 0.019 0.022 0.024 0.122 0.007 0.027 0.024 0.169 0.160 0.069 0.160 0.065 0.160 0.019 0.029 0.160 0.065 0.061 0.025 0.160 0.062 0.061 0.062 0.061 0.062 0.061 0.062 0.061 0.062 0.061 0.063 0.014 0.019 0.026 0.063 0.064 0.011 0.044 0.016 0.033 0.034 0.034 0.033 0.044 0.016 0.033 0.044 0.016 0.033 0.033 0.034 0.016	N Min Max eSD eCV	4 0.040 0.043 0.064 0.005	4 0.006 0.007 0.011 0.000 5	3 0.023 0.024 0.031	0.058	4 0.020 0. 0.024 0. 0.039 0. 0.004 0.	_			5 0.070 0.081 0.258 0.016 20		6 34 0.06 22 0.17(22 0.02 9 22	_			0	5 0.015 0.028 0.094 0.019 69	5 0.024 0.035 0.102 0.011 31	14 0.160 0.209 0.338 0.018 9	14 0.025 0.041 0.152 0.016 38				14 0.092 0.119 0.272 0.021 18
0.043 0.024 0.024 0.017 0.133 0.081 0.083 0.014 0.038 0.028 0.041 0.110 0.251 0.163 0.043 0.007 0.024 0.024 0.017 0.081 0.0134 0.038 0.028 0.044 0.016 0.251 0.163 0.025 0.025 0.021 0.022 0.021 0.022 0.034 0.011 0.044 0.016 0.034	N _{past} lan _{past} SD _{past}		0	6 0.025 0.005	5 0.031 0.008	4 0.023 0. 0.008 0.		14 0.148 0.030		16 0.089 0.1 0.019 0.0	8 24 0.13 22 0.02						0	0	20 0.222 0.044	0	23 0.119 0. 0.019 0.			14 0.120 0.044
	NAV NAU	0.043	0.007							0.081 0.016	0.13	34 0.08 35 0.02	-	3 0.014 2 0.008			0.028 0.019	0.035 0.011	0.209 0.044					0.119 0.025

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Lab	392	393	393 394a 394b 395	394b	395	396	392	393	393 394a 394b 395	394b	395	396
	FSV-BA												
	FSV-BB												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					0000		00	000	0000		0000		
		1.12	0.05		0.990	0.78	1.02	1.209	0.399		0.869	4.665	0.27
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$													
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		00				i	1						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		1.03		0.850		0.71	CI.I						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FUV-BK												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-BL												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-BM												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-BN												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-BNa												
1.33 0.65 0.840 0.71 1.08 1.33 0.65 0.840 0.71 1.08 0.73 0.48 0.670 0.53 0.77 1.08 1.08 0.79 1.227 0.94 1.09 1.727 0.88 0.56 0.860 0.66 1.02 0.613 0.161 0.504 1.727 0.88 0.56 0.890 0.56 1.022 0.94 1.09 1.727 0.73 0.48 0.56 0.890 0.53 0.77 0.613 0.161 1.727 0.73 0.48 0.670 0.890 0.504 0.866 3.196 1.33 0.79 0.860 1.227 0.94 1.16 1.727 0.73 0.16 0.10 0.10 0.10 0.10 0.9504 0.866 3.196 1.33 0.75 0.94 0.66 0.9399 4.665 0.233 0.161 0.70 0 0 0 0 0 0 0 0 0 0 0 0 <td>FSV-RO</td> <td>0.80</td> <td>0 49</td> <td></td> <td>0 8 90</td> <td>0.62</td> <td>0 79</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	FSV-RO	0.80	0 49		0 8 90	0.62	0 79						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		20.00	2		0000	10.0							
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$													
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	FSV-BQ												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	FSV-BR												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-RS												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$													
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$													
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-BU												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-BV												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-RW	1 33		0 840		0 71	1 08						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		20.1		010.0			00.1						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	L0 /- / CL												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-CE												
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	FSV-CG												
$ \left[\begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-CI	0.73		0.670		0.53	0.77	0.613	0.161	0.504		1.727	0.12
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	FSV-CO												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	F0//01	1 08	0 70		1 227	0 04	1 00						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		00.1	0.10		77.	t	50.1						
$ \left[\begin{array}{cccccccccccccccccccccccccccccccccccc$	F3V-UU												
0.88 0.56 0.860 0.66 1.02 7 7 4 3 7 7 2 1 1 2 7 7 4 3 7 7 2 2 1 1 72 0.73 0.845 0.990 0.51 1.02 0.911 0.280 3.196 1.03 0.65 0.845 0.990 0.71 1.02 0.911 0.280 3.196 1.33 0.79 0.860 1.227 0.94 1.16 1.727 1.33 0.79 0.860 1.227 0.94 1.16 4.665 0.23 0.13 0.10 0.10 0.10 0.10 4.665 0.22 20 2 15 10 0	FSV-DV												
$\left[\begin{array}{cccccccccccccccccccccccccccccccccccc$	FSV-EE	0.88	0.56			0.66	1.02						
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	FSV-EZ												
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	ECV/EK												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$													
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	71-701	I	I	•	(I	I	((•	•	(
0.73 0.48 0.670 0.890 0.53 0.77 0.613 0.161 1.727 1.03 0.65 0.845 0.990 0.71 1.02 0.911 0.280 0.504 0.869 3.196 1.33 0.79 0.860 1.227 0.94 1.15 1.209 0.399 4.665 0.23 0.13 0.015 0.10 0.10 22 20 2 15 10 0 0 5 8 9 9 0 0 0 0 0 0 0 0.887 1.044 0.73 0.99 0.171 0.136 0.07 0.03 1.103 0.65 0.845 0.990 0.71 1.02 0.23 0.13 0.10 0.10 0.10	z	-	-	4	n		-	N	N	-	-	N	
1.03 0.65 0.845 0.990 0.71 1.02 0.911 0.280 0.504 0.865 3.196 1.133 0.79 0.860 1.227 0.94 1.15 1.209 0.399 4.665 0.23 0.13 0.015 0.10 0.10 0.10 4.665 22 20 2 15 10 0 0 0 0 0 0 5 8 9 9 0 0 0 0 0 0 0 5 8 9 9 0	Min	0.73	0.48	0.670	0.890		0.77	0.613	0.161			1.727	0.12
1.33 0.79 0.860 1.227 0.94 1.15 1.209 0.399 4.665 0.23 0.13 0.015 0.10 0.10 0.10 22 20 2 4.665 22 20 2 15 10 0.10 0.10 0 0 0 0 0 0 0 5 8 9 9 0 <td>Median</td> <td>1.03</td> <td>0.65</td> <td>0.845</td> <td>066.0</td> <td>0.71</td> <td>1.02</td> <td>0.911</td> <td>0.280</td> <td></td> <td>0.869</td> <td>3.196</td> <td>0.20</td>	Median	1.03	0.65	0.845	066.0	0.71	1.02	0.911	0.280		0.869	3.196	0.20
0.23 0.13 0.015 0.10 0.10 22 20 2 15 10 0 0 5 8 9 9 0 0 0 0 0 0 0.171 0.136 0.07 0.03 1.03 0.65 0.845 0.990 0.71 1.02 0.23 0.13 0.10 0.10 0.10	Мах	1.33	0.79	0.860	1.227	0.94	1.15	1.209	0.399			4.665	0.27
0.22 0.10 0.10 0.10 0.10 22 20 2 15 10 0 0 5 8 9 9 0 0 0 0 0 5 8 9 9 0 0 0 0 0.171 0.136 0.07 0.03 1.033 0.65 0.845 0.990 0.71 1.02 0.23 0.13 0.10 0.10 0.10		0.00	0,10						0000				
22 20 2 13 10 0 5 8 9 9 0 0 0 0 0.887 1.044 0.73 0.99 0.171 0.136 0.07 0.03 1.03 0.65 0.845 0.990 0.71 1.02 0.23 0.13 0.10 0.10		0.420	2.0			2	2.0						
0 0 5 8 9 9 0 0 0 0.887 1.044 0.73 0.99 0.171 0.136 0.07 0.03 1.03 0.65 0.845 0.990 0.71 1.02 0.23 0.13 0.10 0.10	eC<	7	D2	V		ŝ	2						
0.887 1.044 0.73 0.171 0.136 0.07 1.03 0.65 0.845 0.990 0.71 0.23 0.13 0.10	Npast	0	0	5	8	റ	റ	0	0	0	0	0	
0.171 0.136 0.07 1.03 0.65 0.845 0.990 0.71 0.23 0.13 0.10	Aedian past			0.887	1.044		0.99						
1.03 0.65 0.845 0.990 0.71 0.23 0.13 0.10 0.10	SDpast			0.171	0.136	0.07	0.03						
1.03 0.65 0.845 0.990 0.71 0.23 0.13 0.10		00			0000	Ì	00						
0.23 0.13 0.10		1.03	0.65		0.990	0.71	1.02						
		0.23	0.13			0.10	0.10						

All Lab Report

Analytes Reported By One Laboratory Values in µg/mL

 Analyte
 Code
 392
 393
 394a
 394b
 395
 396

 25-hydroxyvitamin D
 FSV-BH
 0.021
 0.023
 0.008
 0.021
 0.026

 Phytoene
 FSV-BS
 0.113
 nq
 0.140
 nq
 0.124

 Phytofluene
 FSV-BS
 0.171
 0.068
 0.296
 0.203
 0.196

 trans-Retinol
 FSV-BR
 0.650
 0.225
 0.460
 0.440
 0.450

Legend

Term	Definition
N	Number of (non-NIST) quantitative values reported for this analyte
Min	Minimum (non-NIST) quantitative value reported
Median	Median (non-NIST) quantitative value reported
Max	Maximum (non-NIST) quantitative value reported
eSD	Adjusted median absolute deviation from the median of the non-NIST results
eCV	Coefficient of Variation for (non-NIST) results: 100*SD/Median
N _{past} Median _{past} SD _{past}	Mean of N(s) from past RR(s) Mean of Median(s) from past RR(s) Pooled SD from past RR(s)
CDpast	
NAV	NIST Assigned Value
	= (Median + NIST)/2 for analytes reported by NIST
	= Median for analytes reported by \geq 5 labs but not NIST
NAU	NIST Assigned Uncertainty: $\sqrt{(S^2 + S_{btw}^2)}$
	S is the maximum of (0.05*NAV, SD, SD _{past} , eSD) and S _{btw} is the standard deviation between Median and NIST. The expected long-term SD, eSD, is defined in: Duewer et al., Anal Chem 1997;69(7):1406-1413.
nd	Not detected (i.e., no detectable peak for analyte)
nq	Detected but not quantitatively determined
<x< td=""><td>Concentration at or below the limit of quantification, x</td></x<>	Concentration at or below the limit of quantification, x
≥x	Concentration greater than or equal to x
!	Discrepant value: damaged sample, interferent, instrument malfunction, etc.
italics	Not explicitly reported but calculated by NIST from reported values

Comparability Summary

Lab	TR	аT	g/bT	bC	tbC	aC	TLv	TbX	TLu	ΤZ	L&Z	Label Definition
FSV-BA	1	1	1	1	1	1	1	1	-		1	Lab Participant code
FSV-BB	1	1	1	1	1	1	1	1	1	1	1	TR Total Retinol
FSV-BC	2											aT α-Tocopherol
FSV-BD	2	2										g/bT γ/β-Tocopherol
FSV-BE	1	1	1	1								bC Total β-Carotene
FSV-BF	4	2		3								tbC trans-β-Carotene
FSV-BG	1	1	1	1		1	1	1			1	aC Total α -Carotene
FSV-BH	1	1	1	1		1	2	2	1	1	3	TLy Total Lycopene
FSV-BJ	1	1	1	2		1	1	1	1			TbX Total β-Cryptoxanthin
FSV-BK	1	1										TLu Total Lutein
FSV-BL	1	1										TZ Total Zeaxanthin
FSV-BM	2	2										L&Z Total Lutein & Zeaxanthin
FSV-BN	1	2		1		1	1	1			1	
FSV-BNa	1	1		2	2	1	1	1	1	1	1	n number of participants providing quantitative data
FSV-BO	1	1	1	1								% 1 Percent of CS = 1 (within 1 SD of medians)
FSV-BP	1	2		4		3	4	4			4	% 2 Percent of CS = 2 (within 2 SD of medians)
FSV-BQ	1	2										% 3 Percent of CS = 3 (within 3 SD of medians)
FSV-BR	1	1										% 4 Percent of CS = 4 (3 or more SD from medians)
FSV-BS				4	4	4	4	4	4	4	4	
FSV-BT	2	1	1	1	1	1	1	1			1	
FSV-BU	3	2	2	1		1	1	1			1	"Comparability Score"
FSV-BV	4	2	1	1		1	2	2			1	The Comparability Score (CS) summarizes your measurement
FSV-BW	1	1	1	2		3	1					performance for a given analyte relative to the consensus medians in this study. CS is the average distance (in units of
FSV-CD	1	3	2	4		2	1	2			3	standard deviation) of your measurement performance
FSV-CE	4	4										characteristics from the consensus performance. CS is
FSV-CG	1	2	1	1	1	1	1	2			2	calculated when the number of quantitative values you reported,
FSV-CI	1	1	3	1		1			1	1	1	N _{you} , is at least two and at least six participants reported quantitative values for the analyte.
FSV-CO		1	1	1			1					
FSV-CZ	3	2	2	4								We define CS as follows:
FSV-DD	2											$CS = MINIMUM \left(4, INTEGER \left(1 + \sqrt{C^2 + AP^2} \right) \right)$
FSV-DV	2	1										
FSV-EZ	4	1	1	3								$\sum_{i=1}^{N_{you}} \frac{You_i - Median_i}{You_i - Median_i}$
FSV-FK	1	1										$C = Concordance = \frac{\sum_{i=1}^{i} NAU_i}{i}$
FSV-FZ		1	1	2								N _{you}
n	32	31	18	23	6	16	16	14	6	5	14	$\sum_{i=1}^{N_{you}} (You_i - Median_i)^2$
		_				_					–	
04.4			g/bT									AP = Apparent Precision = $1 \frac{1 + 1 + 1 + 1 + 1}{N_{you} - 1}$
% 1 % 2	59	61	78	57	67	75	75	57	83	80	64	NAU = NIST Assigned Uncertainty
% 2 % 2	19		17	17	17	6	13	29	0	0	7	
%3	9	3	6	9	0	13	0	0	0	0	14	For further details, please see
% 4	13	3	0	17	17	6	13	14	17	20	14	Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT. Micronutrients Measurement Quality Assurance

Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT. Micronutrients Measurement Quality Assurance Program: Helping participants use interlaboratory comparison exercise results to improve their long-term measurement performance. Anal Chem 1999;71(9):1870-8.

Appendix D. Representative Individualized Report for RR73

Each participant in RR73 received an "Individualized Report" reflecting their reported results. Each report included a detailed analysis for analytes that were assayed by at least five participants. The following analytes met this criterion:

- Total Retinol
- Retinyl Palmitate
- α-Tocopherol
- γ/β -Tocopherol
- Total β-Carotene
- *trans*-β-Carotene
- Total *cis*-β-Carotene
- Total α-Carotene
- Total Lycopene
- *trans*-Lycopene
- Total β-Cryptoxanthin
- Total Lutein
- Total Zeaxanthin
- Total Lutein & Zeaxanthin
- Coenzyme Q10

The following fourteen pages are the "Individualized Report" for the analytes evaluated by participant FSV-BA.

Set 6 of 35

Individualized Round Robin LXXIII Report: FSV-BA

		c	31	9	31	18	4	20	9	S	4	15	~	13	4	13
	Serum 396	NAV	0.475	0.02	7.21	1.800	0.109	0.053	0.047	0.005	0.023	0.249	0.120	0.095	0.017	0.119
	Seru	You	0.484	0.03	7.11	1.897	0.126	0.052	0.045	0.007	0.020	0.214	0.104	0.101	0.014	0.105
		L	31	∞	31	18	2	21	9	S	15	15	~	13	4	13
	Serum 395	NAV	0.463	0.05	11.21	1.387	0.093	0.666	0.612	0.039	0.355	0.288	0.130	0.067	0.024	0.165
	Seru	You	0.452	0.06	10.78	1.416	0.083	0.636	0.597	0.039	0.340	0.260	0.130	0.071	0.026	0.151
	0	c	10		ი	9	2	~	~	~	ო	ო	-	ო	~	ო
	Serum 394b	NAV	0.317		8.40	2.950		0.294			0.042	0.513		0.128		0.251
	Ser	You														
		L	21	~	22	12	ო	14	2	4	1	12	9	ი	ო	ω
	Serum 394a	NAV	0.470	0.0	6.88	1.890	0.117	0.328	0.301	0.020	0.030	0.332	0.176	0.054	0.024	0.114
Summary		You	0.470	0.0	6.95	2.002	0.117	0.332	0.309	0.023	0.030	0.307	0.171	0.061	0.031	0.103
Sun		c	31	S	31	18	4	16	S	4	1	15	2	1	4	13
	Serum 393	NAV	0.243	0.0	4.15	0.800	0.062	0.016	0.013	0.005	0.006	0.144	0.071	0.012	0.007	0.040
	Seru	You	0.262	0.0	4.09	0.839	0.040	0.019	0.014	0.005	0.004	0.135	0.071	0.011	0.006	0.033
		c	31	∞	31	18	4	21	9	S	15	15	~	12	4	13
	Serum 392	NAV	0.675	0.16	8.37	3.913	0.704	0.476	0.450	0.019	0.421	0.352	0.246	0.058	0.042	0.216
	Seru	You	0.724	0.08	8.53	4.331	0.749	0.299	0.286	0.013	0.372	0.299	0.204	0.059	0.046	0.179
		Analyte	Total Retinol	Retinyl Palmitate	α-Tocopherol	γ/β-Tocopherol	ō-Tocopherol	Total β-Carotene	trans-β-Carotene	Total cis-β-Carotene	Total α-Carotene	Total Lycopene	trans-Lycopene	Total β-Cryptoxanthin	Total α-Cryptoxanthin	Total Lutein&Zeaxanthin

You : Your reported values for the listed analytes (micrograms/milliliter)

NAV : NIST Assigned Values, here equal to this RR's median

n : Number of non-NIST laboratories reporting quantitative values for this analyte in this serum

Tel: (301) 975-3935 Fax: (301) 977-0685 Email: david.duewer@nist.gov


Please check our records against your records. Send corrections and/or updates to...

Micronutrients Measurement Quality Assurance Program


National Institute of Standards and Technology

100 Bureau Drive Stop 8392 Gaithersburg, MD 20899-8392 USA Page 1 / 14


Individualized Report




<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385




<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385




<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385



<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385




<u>Serum</u>	Comments	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385




<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385






<u>Serum</u>	Comments	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385




<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385



<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385

Individualized RR LXXIII Report: FSV-BA




For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

<u>Serum</u>	Comments	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385

Individualized RR LXXIII Report: FSV-BA

Total β-Cryptoxanthin, µg/mL



For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

<u>Serum</u>	Comments	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385


Individualized RR LXXIII Report: FSV-BA

Total Lutein&Zeaxanthin, µg/mL 0 Your [Analyte], µg/mL [Analyte], µg/mL 0 0 353 -371 394b 382 . 395 . Median [Analyte], µg/mL 224 392 271 275 279 296 308 394a 385 396 393 Apparent Precision, SD Apparent Precision, SD + Long-term Precision, SD Concordance, SD 3rd Quartile (75%) You, this RR You, ≥x, this RR Median (50%) You, past RRs △ You, ≥x, past RRs Others, this RR O 1st Quartile (25%) Expectation

For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

<u>Serum</u>	<u>Comments</u>	<u>History</u>
#392	Lyophilized, augmented, multi-donor	38#224
#393	Fresh-frozen, native, multi-donor	New
#394a	Fresh-frozen, augmented, single-donor	49#271, 50#275, 51#279, 54#296, 56#308
#394b	Fresh-frozen, augmented, multi-donor	65#353, 68#371
#395	Fresh-frozen, native, multi-donor	71#382
#396	Fresh-frozen, native, multi-donor	71#385

 $[ILR_RR73_FSV-BA.XLSx]Target$, Page 14 / 14



D15

5/17/2013

Appendix E. Shipping Package Inserts for RR38

The following three items were included in each package shipped to an RR38 participant:

- Cover letter
- Analysis of Control Materials and Test Samples Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter and datasheet were enclosed in a sealed waterproof bag along with the samples themselves. The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.



January 21, 2013

Dear Colleague:

The samples within this package constitute Vitamin C Round Robin 38 (RR38) of the 2013 Micronutrients Measurement Quality Assurance Program. RR38 consists of one vial each of four frozen serum *test samples* (#381, #382 #383, and #384) and one vial each of two frozen *control sera* (CS#3 and CS#4). These materials are in sealed ampoules. They were prepared by adding equal volumes of 10% MPA to spiked human serum. We have checked the samples for stability and homogeneity. Only total ascorbic acid is stable. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, only <u>total ascorbic acid</u> should be analyzed and reported.

Please use the *control sera* to validate the performance of your measurement system <u>before</u> you analyze the *test samples*. The target value for CS#3 is $(15.5 \pm 1.6; 13.9 \text{ to } 17.1) \mu \text{mol/L}$ and the target for CS#4 is $(46.1 \pm 4.6; 41.5 \text{ to } 50.7) \mu \text{mol/L}$. We expect your results for both of these controls to be within this $\pm 10\%$ target range. If your results are significantly outside this range, your analysis system may not be suited to the analysis of MPA-preserved samples. In this case, please do **not** proceed to the analysis of the *test samples* but contact us at 301-975-3120 or jbthomas@nist.gov.

The test samples and control sera should be defrosted by warming at 20 °C for not more than 10 min otherwise some irreversible degradation may occur. Please be aware that sample contact with any oxidant-contaminated surface (vials, glassware, etc.) may degrade your measurement system's performance (SA Margolis and E Park, "Stability of Ascorbic Acid in Solutions in Autosampler Vials", *Clinical Chemistry* 2001, 47(8), 1463-1464). You should suspect such degradation if you observe unusually large variation in replicate analyses.

Please measure the total ascorbic acid in each ampoule in duplicate, reporting in units of $\mu mol/(L sample solution)$ rather than $\mu mol/(L serum used to prepare the sample)$. Please email (david.duewer@nist.gov) or fax (301-977-0685) your results to us as soon as possible but no later than April 1, 2013.

If you have questions or comments regarding this study, please e-mail me at jbthomas@nist.gov or call me at (301) 975₁₃3120.

Jeanice Brown Thomas Program Coordinator/Research Chemist Analytical Chemistry Division Chemical Science and Technology Laboratory

Sincerely.

Enclosure: RR38 Report Form for Control Material and Test Sample Analyses



Vitamin C Round Robin 38 NIST Micronutrients Measurement Quality Assurance Program

Packing List and Shipment Receipt Confirmation Form

This box contains one vial each of the following **six** VitC M^2QAP samples:

Label	Form
VitC #381	Liquid frozen (1:1 serum:10% MPA)
VitC #382	Liquid frozen (1:1 serum:10% MPA)
VitC #383	Liquid frozen (1:1 serum:10% MPA)
VitC #384	Liquid frozen (1:1 serum:10% MPA)
CS #3	Liquid frozen (1:1 serum:10% MPA)
CS #4	Liquid frozen (1:1 serum:10% MPA)

Please 1) Open the pack immediately

- 2) Check that it contains one vial each of the above samples
- 3) Check if the samples arrived frozen
- 4) Store the samples at -20 °C or below until analysis
- 5) Email (david.duewer@nist.gov) or fax (301-977-0685) us the following information:

1) Date this shipment arrived: _____

2) Are all of the vials intact? Yes | No If "No", which one(s) were damaged?

- 3) Was there any dry-ice left in cooler? Yes | No
- 4) Did the samples arrive frozen? Yes | No
- 5) At what temperature are you storing the samples? _____ °C
- 6) When do you anticipate analyzing these samples? _____

Your prompt return of this information is appreciated.

The M²QAP Gang

Appendix F. Final Report for RR38

The following three pages are the final report for RR38 as provided to all participants:

- Cover letter.
- An information sheet that:
 - o describes the contents of the "All-Lab" report,
 - o describes the content of the "Individualized" report,
 - describes the nature of the test samples and details their previous distributions, if any, and
 - summarizes aspects of the study that we believe may be of interest to the participants.



May 16, 2013

Dear Colleague:

Enclosed is the summary report of the results for Round Robin 38 (RR38) for the measurement of total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid) in human serum. Included in this report are a summary of data for all laboratories and an individualized summary of your laboratory's measurement performance. The robust median is used to estimate the consensus value for all samples, the "adjusted median absolute deviation from the median" (MADe) is used to estimate the expected standard deviation, and we estimate the coefficient of variation (CV) as 100×MADe/median.

RR38 consisted of four test samples (#381, #382,, #383, and #384), one vial each of two frozen control serum control samples (CS #3 and CS #4), and one vial of solid control material (Control) for preparation of TAA control solutions. Details regarding the samples can be found in the enclosed report.

If you have concerns regarding your laboratory's performance, we suggest that you obtain and analyze a unit of Standard Reference Material (SRM) 970 Vitamin C in Frozen Human Serum. SRM 970 can be purchased from the NIST SRM Program at <u>www.nist.gov/srm</u>; phone: 301-975-6776; fax: 301-948-3730. If your measured values do not agree with the certified values, we suggest that you contact us for consultation.

Samples for the second vitamin C round robin (RR39) of the 2013 MMQAP will be shipped starting June 10, 2013. Please contact us immediately if this schedule is problematic for your laboratory.

We are currently in the process of providing on-line documentation of data and reports from the MMQAP studies (past and present). The results for Round Robin 71 Fat-Soluble Vitamins and Carotenoids in Human Serum and and Round Robin 36 Ascorbic Acid in Human Serum are available at: http://www.nist.gov/manuscript-publication-search.cfm?pub_id=911458. Click on the DOI link to access the manuscript. Data summaries have been altered to ensure confidentiality of identification codes assigned to laboratories. We will update you as additional documents become available on-line.

If you have questions or concerns regarding this report, please contact David Duewer at david.duewer@nist.gov or me at jbthomas@nist.gov, 301-975-3120, or fax: 301-977-0685.

Sincerely,

Jeanice Brown Thomas, M.B.A . Research Chemist Analytical Chemistry Division Material Measurement Laboratory

Enclosures

cc: L. C. Sander

UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology

Gaithersburg, Maryland 20899-

David L. Duewer, Ph.D. Research Chemometrician Analytical Chemistry Division Material Measurement Laboratory



The NIST MMQAP Vitamin C Round Robin 38 (RR38) report consists of:

Page	"Individualized" Report
1	Summary of your reported values for the two serum control and four serum test samples.
2	Graphical summary of your RR38 measurements.
Page	"All-Lab" Report
1	A tabulation of results and summary statistics for total ascorbic acid [TAA] in the RR38 control and test samples. Results and summary statistics are also presented for the test samples calibrated to the results for the control samples
Serum-Ba	ased Samples. Two serum controls and four test samples were distributed in RR38.
CS#3	a (15.4 \pm 0.4) µmol/L material ampouled in 2009
CS#4	a (46.2 \pm 1.2) µmol/L material ampouled in 2009
S38:1	an unaugmented material (i.e., the [TAA] content is zero or nearly so), ampouled in 2001, previously distributed in RRs 16, 19, 21, 23, 26, and 29
S38:2	Ampouled in late 2009, previously distributed in RRs 32, 33, and 35
S38:3	Ampouled in late 2009, previously distributed in RRs 32, 35, and 36
S38:4	Ampouled in late 2009, previously distributed in RRs 34 and 36

Results.

- 1) The reported [TAA] contents of the two control sera, CS#3 and CS#4, are unchanged from the values estimated for these materials when they were distributed as unknowns. The expected [TAA] content and inter-participant standard deviation are estimated with the robust median and adjusted median absolute deviation (eSD) statistics.
- 2) All participants reported either "zero" or credible limit-of-quantification (LoQ) values for the unaugmented (nominal zero-level) material, S38:1. We regard providing LoQ (i.e., "<*x*") values to be the more informative reporting practice.
- 3) The reported [TAA] contents of the three non-blank test samples, S38:2 to S38:4, are the same as estimated in previous studies. The robust inter-participant estimated coefficient of variation

$$eCV = 100 eSD/Median$$

pooled over these three materials is 8%.

4) The results for two control sera with well-separated [TAA] levels enable calibration of the reported results for the unknowns to the function:

$$[TAA]_{reportedCS} = a + b*[TAA]_{referenceCS}$$

where [TAA]_{reportedCS} are the reported values for the two control sera and [TAA]_{referenceCS} are the established reference values for these materials. The calibrated values for unknown samples are then given by:

$$[TAA]_{calibrated} = ([TAA]_{reported} - a) / b$$
.

Figure 1 displays the eSD as a function of the Median values for the test samples distributed in RR37 and RR38 for both the "as reported" and "after calibration" results. While there is as yet too little data to draw strong conclusions, calibration to the control materials appears to improve the pooled eCV of the seven test samples from about 7% to 5%.




Figure 1: Estimated Standard Deviation as a Function of Median Value Each symbol represents the summary statistics for one of the four test samples distributed in RR37 or one of the three non-blank test samples distributed in RR38.

Appendix G. "All-Lab Report" for RR38

The following two pages are the "All-Lab Report" for RR38 as provided to all participants, with the following exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.
- the Legend page has been added.

The data summary in the "All-Lab Report" has been altered to ensure confidentiality of identification codes assigned to laboratories.

Micronutrients Measurement Quality Assurance Program for Total Ascorbic Acid "Round Robin" 38 - Winter 2013

n/l	S38:4'	57.4	54.6	57.0	53.1	56.2	55.2	61.6	56.7	56.7	6	56.5	2.4		53.1	55.2	56.7	57.0	61.6	1.0	C
<u>nol/L</u>	S38:3'	31.3	33.9	31.1	29.0	31.9	29.5	32.6	31.4	31.6	6	31.4	1.5		29.0	31.1	31.4	31.9	33.9	0.8	(
TAA]', µmol/l	S38:2' §	23.0	22.9	23.7	22.0	23.6	21.6	24.1	24.8	24.3	6	23.3	1.0		21.6	22.9	23.6	24.1	24.8	0.9	
calibrated results. [1 AA] = ([1 AA] - a)/0 [rameters] [TAA]', µmol/L	S38:1' S	<7.0	pu	0.8	<0.9	<6.4	<1.3	-1.4	<0.9	<8.4	2	-0.3	1.6		-1.4		-0.3		0.8		
	a	-2.0	-0.1	-0.8	-0.1	-7.8	8.7	1.3	0.9	-2.4	ļ				ļ						
Parameters	q	1.03	1.05	1.03	1.02	1.44	0.97	0.92	0.93	0.97											
	S38:4	57.0	57.2	57.8	53.9	73.3	62.2	57.7	53.6	52.8	6	58.4	6.3		52.8	53.9	57.2	57.8	73.3	4.8	
), µmol/l	S38:3 5	30.2	35.5	31.1	29.4	38.3	37.3	31.2	30.1	28.3	6	32.4	3.7		28.3	30.1	31.1	35.5	38.3	2.6	
oditipies	S38:2 §	21.7	24.0	23.5	22.4	26.2	29.7	23.3	24.0	21.2	6	24.0	2.6		21.2	22.4	23.5	24.0	29.7	1.7	
Total Ascorbic Acid ([TAA]), µmol/l	S38:1 \$	<5.2	pu	0.0	<0.9	<1. 4.	<10	0.0	<1.7	<5.7	2	0.0	0.0		0.0		0.0		0.0		
al Asco	CS#4	45.4	48.3	46.6	46.8	58.8	53.4	43.5	43.7	42.5	6	47.7	5.3		42.5	43.7	46.6	48.3	58.8	4.3	
Tot	CS#3	13.9	16.2	15.1	15.7	14.6	23.8	15.5	15.3	12.7	6	15.9	3.1		12.7	14.6	15.3	15.7	23.8	1.1	
L	Date	27/02/13	15/05/13	03/04/13	18/03/13	29/03/13	05/03/13	05/04/13	28/03/13	11/03/13	z	Average	SD	l	Min	%25	Median	%75	Max	eSD	
	Lab	/C-MB	/C-MC	/C-MG	/C-MH	VC-MI	VC-MJ	/C-MN	VC-NF	VC-NM											

All Lab Report

Total Ascorbic Acid	
Micronutrients Measurement Quality Assurance Program for Total Ascorbic Acid	"Round Robin" 38 - Winter 2013

Legend

Definition	Participant code Date results received at NIST Slope and Intercept of the line connecting the expected values for control samples CS#3 and CS#4 with the results reported by each participant	Number of quantitative values reported for this analyte Mean of the reported quantitative values Standard deviation of the reported quantitative values	Minimum quantitative value reported First quartile of the reported quantitative values Median (second quartile) of the reported quantitative values Third quartile of the reported quantitative values Maximum quantitative value reported Robust standard deviation, estimated using the adjusted median absolute deviation from the median (MADe) Robust Coefficient of Variation, estimated as 100*eSD/Median	<i>nd</i> Not determined <x concentration="" less="" th="" than="" x<=""></x>
Term	Lab F Date I <i>b</i> 3	Average P SD 5	Min Median Max Max eSD eCV	ud ××

Appendix H. Representative "Individualized Report" for RR38

Each participant in RR38 received an "Individualized Report" reflecting their reported results. The following two pages are the "Individualized Report" for participant "VC-MB".

				[TAA] m	nmol/Ls	ample		_			
Date	RR	Sample	Rep ₁	Rep ₂	F_{adj}	Mean	SD_{dup}	Ν	Mean	SD _{repeat}	SD _{reprod}
07/23/10	33	S33:3	13.4	13.4	1.0	13.4	0.0	5	13.8	1.5	1.2
01/14/11	34	S34:2	13.9	13.9	1.0	13.9	0.0				
06/13/11	35	S35:1	15.0	15.5	1.0	15.2	0.4				
08/06/12	37	CS#3	10.3	15.0	1.0	12.6	3.3				
02/27/13	38	CS#3	13.9	13.9	1.0	13.9	0.0				
			-			-		-			
01/13/10	32	S32:4	45.4	45.9	1.0	45.7	0.4	5	46.1	1.1	1.0
01/14/11	34	S34:3	45.4	45.9	1.0	45.7	0.4				
06/13/11	35	S35:4	47.5	47.5	1.0	47.5	0.0				
08/06/12	37	CS#4	44.9	48.0	1.0	46.5	2.2				
02/27/13	38	CS#4	45.9	44.9	1.0	45.4	0.7				
02/08/02	16	S16:2	3.1	2.0	0.5	1.3	0.4	5	0.9	0.4	1.4
05/01/03	19	S19:1	5.2	7.2	0.5	3.1	0.7				
07/14/04	21	S21:1	<5.2	<5.2	1.0						
05/25/05	23	S23:1	0.0	0.0	1.0	0.0	0.0				
11/26/06	26	S26:1	0.0	0.0	1.0	0.0	0.0				
06/20/08	29	S29:1	0.0	0.0	1.0	0.0	0.0				
01/02/00	38	S38:1	<5.16	<5.16	1.0						
01/13/10	32	S32:2	22.2	22.7	1.0	22.5	0.4	4	22.7	0.4	0.9
07/23/10	33	S33:4	23.2	22.7	1.0	23.0	0.4				
06/13/11	35	S35:2	23.7	23.7	1.0	23.7	0.0				
02/27/13	38	S38:2	21.2	22.2	1.0	21.7	0.7				
01/13/10	32	S32:3	30.5	31.0	1.0	30.7	0.4	4	30.9	0.5	0.7
06/13/11	35	S35:3	32.0	31.5	1.0	31.7	0.4				
03/07/12	36	S36:2	31.5	30.5	1.0	31.0	0.7				
02/27/13	38	S38:3	29.9	30.5	1.0	30.2	0.4				
04/44/44	0.4	004.4	50.0	F7 0	4.0	57 0	0.4	<u> </u>	50.0	07	07
01/14/11	34	S34:4	56.8	57.3	1.0	57.0	0.4	4	56.8	0.7	0.7
03/07/12	36	S36:1	57.8	56.8	1.0	57.3	0.7				
03/07/12	36	S36:4	56.8	55.2	1.0	56.0	1.1				
02/27/13	38	S38:4	57.3	56.8	1.0	57.0	0.4				

Vitamin C "Round Robin" 38 Report: Participant VC-MB


Please check our records against your records. Send corrections and/or updates to...

Micronutrients Measurement Quality Assurance Program National Institute of Standards and Technology

Fax: (301) 977-0685 Email: david.duewer@nist.gov

Vitamin C "Round Robin" 38 Report: Participant VC-MB

Total Ascorbic Acid, µmol/mL



For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Comments

Sample

CS#3 Distributed as an unknown in RRs 33, 34, and 35. Distributed as a control in RR37.
CS#4 Distributed as an unknown in RRs 32, 34, and 35. Distributed as a control in RR37.
S38:1 Zero-level control serum, distributed in RRs 16, 19, 21, 23, 26, and 29
S38:2 Distributed in RRs 32, 33, and 35

- S38:3 Distributed in RRs 32, 35, and 36 $\,$
- S38:4 Distributed in RRs 34 and 36